(Total Views: 326)
Posted On: 04/08/2020 2:59:48 PM
Post# of 72436
It's a possibility after the drug is approved. Assuming Leo is ready to partner Brilacidin's platform after successful oral B-IBD and B-COVID19 phase 2 trials, BP needs to consider more important factors such as cost of phase 3 trials, length to market including time of phase 3 trials for all indications plus FDA review period, and how much time is left in the patent after approval.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)